Clinical Study on the Autologous Stem Cell Transplantation Infused Sequentially with Cord Blood Stem Cell for Refractory and Relapsed Lymphoma

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900025016

Enrollment

Unknown

Registered

2019-08-07

Start date

2023-11-28

Completion date

Unknown

Last updated

2024-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory and relapsed lymphoma

Interventions

experimental group:hybrid stem cell transplantation with autologous stem cell and cord blood stem cell

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years; 2. Eligible for autologous hematopoietic stem cell transplantation; 3. Patients are willing to recieve hybrid stem cell transplantation with autologous stem cell and cord blood stem cell; 4. Patients sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. People with mental disabilities and intelligent obstacle; 2. Pregnant women; 3. Patients don't want to recieve this therapy.

Design outcomes

Primary

Measure	Time frame
Progression-Free-Survival;overall survival;relapse-free survival;	—

Countries

China

Contacts

Public ContactYongqian Jia

West China Hospital, Sichuan University

jia_yq@scu.edu.cn+86 189 8060 1198

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026